Timeliness and actionable intelligence over I-Banks research which remains only geared to institutional investors and legacy processes. News carries with it a promise of transparency, a light that can be shined into previously dark corners.
But they don’t define any relevance to the actual value of a release - mostly due to SEC forward looking parameters. However, this news portal has been expanded to … supplement, measure and price the event and relevance to a company’s ... valuation.
August 17, 2018
Gene editing stocks, time to harvest some upside?
August 15, 2018
Regenerative Medicine Earnings Scorecard - Q2/18 - to date
April 4, 2018
Cellectis (CLLS) prices follow-on $175 M ADS offering
April 27, 2016
Cytori (CYTX) P3 Scleroderma trial update
April 1, 2016
RegMed Investors (RMi) it’s time to act on subscription!
March 31, 2016
Biostage ™ hits the limelight with a quantified focus - BUY
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors